Immuno – Oncology
We concentrate our attention and R&D resources on cancer areas which we have determined to be both demanding and compliant with our virotherapy product development.
Several Types of Sarcoma
Rigvir Group has established an annual objective of announcing a grant competition for publications on clinical studies of oncolytic virotherapy, observations or clinical cases in a publication that can be quoted in PubMed. Along with the financial contribution, the grant applicant name will appear in the Publication as a co-author.
Any doctor or researcher preparing the scientific publication can participate in the competition. The only exception are employees of Rigvir Group and related companies, who cannot participate in the competition. Each grant is given for one article after publishing the article.
The study is intended on using oncolytic virotherapy rather than using oncolytic virotherapy in combination with other cancer therapies, medication etc. Grant applicants should inform on the publication topic and present the document draft before commencing the project and submitting it to the chosen journal.